Abstract: A fluid-filled vibration-damping device including: a first mounting member; a second mounting member; a main rubber elastic body elastically connecting the two mounting members; a fluid chamber whose wall is constituted by the main rubber elastic body at a portion and by a flexible film at another portion, the fluid chamber being filled with a non-compressible fluid; a fixation member being attached to an outer peripheral rim of the flexible film and being disposed inside or outside the tubular second mounting member such that the fixation member is superposed to the second mounting member in an axis-perpendicular direction; an insertion hole formed in the second mounting member and the fixation member; and a positioning member inserted through the insertion hole so as to relatively position the second mounting member and the fixation member at a scaling position by axial locking.

Abstract: A bracket-equipped vibration-damping device including: a vibration-damping device main body including vertically-separated, elastically-connected first and second mounting members; a bracket receiving the device main body inserted laterally thereinto; a connection-insert section provided for the second mounting member; a connection groove provided for the bracket extending in an insertion direction of the device main body; at least one up-down urging rubber fixed on an outer surface of the connection-insert section on an upper-lower first side; and a lock protrusion formed on an inner surface of the connection groove on an upper-lower second side, with a smaller protrusion dimension than an up-down thickness of the up-down urging rubber such that the connection-insert section is laterally inserted into the connection groove beyond the lock protrusion before being urged to the second side by the up-down urging rubber to be positioned to the connection groove.

Abstract: An object of the present invention is to provide a novel dry eye therapeutic agent that demonstrates superior dry eye therapeutic effects, and from the viewpoint of the drug administration burden of the patient, is capable of demonstrating a medicinal effect over a long period of time in lacrimal gland tissue after the administration thereof. A dry eye therapeutic agent comprising nandrolone or an ester thereof or methenolone or an ester thereof is therapeutically effective on dry eye since it increases the amount of tear lipocalin (TL) in tears, and medicinal effects can be demonstrated over a long period of time in lacrimal gland tissue by administering a dry eye therapeutic agent comprising nandrolone or an ester thereof or methenolone or an ester thereof to eyelid skin.

Abstract: A bracket-equipped vibration-damping device including: a vibration-damping device main body including vertically-separated, elastically-connected first and second mounting members; a bracket receiving the device main body inserted laterally thereinto; a connection-insert section provided for the second mounting member; a connection groove provided for the bracket extending in an insertion direction of the device main body; at least one up-down urging rubber fixed on an outer surface of the connection-insert section on an upper-lower first side; and a lock protrusion formed on an inner surface of the connection groove on an upper-lower second side, with a smaller protrusion dimension than an up-down thickness of the up-down urging rubber such that the connection-insert section is laterally inserted into the connection groove beyond the lock protrusion before being urged to the second side by the up-down urging rubber to be positioned to the connection groove.

Abstract: A fluid-filled vibration-damping device including: a first mounting member; a second mounting member; a main rubber elastic body elastically connecting the two mounting members; a fluid chamber whose wall is constituted by the main rubber elastic body at a portion and by a flexible film at another portion, the fluid chamber being filled with a non-compressible fluid; a fixation member being attached to an outer peripheral rim of the flexible film and being disposed inside or outside the tubular second mounting member such that the fixation member is superposed to the second mounting member in an axis-perpendicular direction; an insertion hole formed in the second mounting member and the fixation member; and a positioning member inserted through the insertion hole so as to relatively position the second mounting member and the fixation member at a scaling position by axial locking.

Abstract: A bracket-equipped vibration-damping device including: a vibration-damping device main unit including first and second mounting members disposed separately from each other vertically and connected by a main rubber elastic body mutually and elastically; and a bracket mounted to the device main unit in a state that the bracket is fixed to the second mounting member inserted into the bracket laterally. A guide part of the second mounting member is inserted into a guide groove of the bracket extending in an insertion direction to be positioned vertically. The bracket includes a compression wall surface superposed to at least one of upper and lower end surfaces of the device main unit. A groove width inner surface of the guide groove opposite vertically to the compression wall surface is tilted to the compression wall surface so that the surfaces approach each other vertically toward the insertion direction.

Abstract: A bracket-equipped vibration-damping device including: a vibration-damping device main unit including first and second mounting members disposed separately from each other vertically and connected by a main rubber elastic body mutually and elastically; and a bracket mounted to the device main unit in a state that the bracket is fixed to the second mounting member inserted into the bracket laterally. A guide part of the second mounting member is inserted into a guide groove of the bracket extending in an insertion direction to be positioned vertically. The bracket includes a compression wall surface superposed to at least one of upper and lower end surfaces of the device main unit. A groove width inner surface of the guide groove opposite vertically to the compression wall surface is tilted to the compression wall surface so that the surfaces approach each other vertically toward the insertion direction.

Abstract: The purpose of the present invention is to provide a novel injectable agent having an excellent medicinal agent sustained release property. The injectable agent according to the present invention comprises a medicinal agent, trehalose and gellan gum. It is preferred that the contents of the medicinal agent, trehalose and gellan gum are 0.0001 to 50.00% (w/v), 0.1 to 50.0% (w/v) and 0.01 to 3.00% (w/v), respectively, relative to the total volume of the injectable agent. It is also preferred that the injectable agent can form a depot upon exposure to a phosphate buffer solution or a body fluid (tear fluid, vitreous fluid, etc.).

Abstract: A method for treating a TRPV1-mediated disease by administering to a patient a therapeutically effective amount of a compound or a salt thereof having the following formula [I]: wherein A represents a lower alkylene group or a lower alkenylene group; R1 represents a hydrogen atom, an unsubstituted or substituted alkyl group or an unsubstituted or substituted alkenyl group; and R2 and R3 are the same or different and represent a hydrogen atom, an unsubstituted lower alkyl group or a lower alkyl group substituted by a monocyclic cycloalkyl group, a polycyclic cycloalkyl group or an aryl group.

Abstract: A first computer establishes a connection between a second computer and the first computer when a specific request for access to a specific path from the second computer is accepted. The first computer transmits to the second computer a script for enabling the second computer to perform a proxy process of accepting a database access request for access to a database from an application to be accessed by the second computer, accessing the database, and acquiring an access result from the database. Then, the first computer receives a database access result from the second computer, and outputs the result to the application.

Abstract: Perfluoropolymer composites are provided which are obtained by dispersing layered-silicates having properties of swelling or cleaving in dispersion media in perfluoropolymers and having the ratio of the viscosity, V0.1, at 0.1 rad/sec by a parallel plate mode of a dynamic rheometer to the viscosity, V1, measured at 1 rad/sec is 1.5 or greater, viscosity being measured at 340° C. A method for making the perfluoropolymer composites is provided, and molded articles therefrom. And additionally, perfluoropolymer composites, where layered-silicates having properties of swelling or cleaving in dispersion media are dispersed in perfluoropolymers, with the storage elasticity of 2 times or higher than that of fluoropolymers, at temperatures greater than the glass transition temperature of perfluoropolymers.

Abstract: The object aims to find a novel pharmacological activity of a novel 1,2,3,4-tetrahydroquinoxaline derivative which contains, as a substituent, a phenyl group having a sulfonic acid ester structure introduced therein. A compound represented by general formula (1) or a salt thereof is useful as a glucocorticoid receptor agonist, particularly as a therapeutic agent for diseases against which a glucocorticoid receptor agonist (e.g., a steroid) is believed to be effective, such as inflammatory bone/joint diseases, inflammatory ophthalmic diseases (inflammatory ophthalmic diseases in the anterior or posterior segment of an eye).

Abstract: A method for treating a non-ocular inflammatory disease comprising administering to a patient in need thereof a therapeutically effective amount of a compound represented by the following formula (1) or a salt thereof: R1 represents: R2 represents a lower alkyl group, a lower cycloalkyl group or an aralkyl group; R3 represents a lower alkyl group; R4, R5, R6 or R7 each represents a halogen atom, a lower alkyl group, a hydroxyl group, a lower alkoxy group, a cyano group or a nitro group; m, n, p or q each represents 0, 1 or 2; in the case where m, n, p or q is 2, each of R4, R5, R6 or R7 is the same or different.

Abstract: A polypeptide according to the present invention includes: an altered polypeptide obtained by altering an ArgRS, a CysRS, a MetRS, a GlnRS, a GluRS, a LysRS, a TyrRS, or a TrpRS so that an unnatural amino acid is recognized; and an editing polypeptide derived from a PheRS, a LeuRS, an IleRS, a ValRS, an AlaRS, a ProRS, or a ThrRS, the editing polypeptide having been either inserted between a Rossman-fold N domain and a Rossman-fold C domain that exist in the altered polypeptide, or bound to an N terminal of the altered polypeptide. Thus provided are a new aaRS that exhibits high substrate specificity to an unnatural amino acid and a technique that involves the use of such an aaRS.

Abstract: A water pump attachment structure of a water-cooled internal combustion engine is provided to facilitate the maintenance of a valve train. A water pump attachment structure of a water-cooled internal combustion engine includes a semicircular cut-away surface of a water pump holder opposed to a semicircular surface of a cylinder head to form a water pump support circular hole. Screw members are passed through respective screw through-holes of the cylinder head and threadedly engaged with internal thread holes of the water pump holder. Thus, the water pump holder is fastened to the cylinder head. A water pump is fitted into and secured to the water pump support circular hole. A cylinder head cover is attached to the cylinder head by allowing their mating surfaces to conform with each other with the water pump holder liquid-tightly sandwiched therebetween.

Abstract: A first computer establishes a connection between a second computer and the first computer when a specific request for access to a specific path from the second computer is accepted. The first computer transmits to the second computer a script for enabling the second computer to perform a proxy process of accepting a database access request for access to a database from an application to be accessed by the second computer, accessing the database, and acquiring an access result from the database. Then, the first computer receives a database access result from the second computer, and outputs the result to the application.

Abstract: A polypeptide according to the present invention includes: an altered polypeptide obtained by altering an ArgRS, a CysRS, a MetRS, a GlnRS, a GluRS, a LysRS, a TyrRS, or a TrpRS so that an unnatural amino acid is recognized; and an editing polypeptide derived from a PheRS, a LeuRS, an IleRS, a ValRS, an AlaRS, a ProRS, or a ThrRS, the editing polypeptide having been either inserted between a Rossman-fold N domain and a Rossman-fold C domain that exist in the altered polypeptide, or bound to an N terminal of the altered polypeptide. Thus provided are a new aaRS that exhibits high substrate specificity to an unnatural amino acid and a technique that involves the use of such an aaRS.

Abstract: The object aims to find a novel pharmacological activity of a novel 1,2,3,4-tetrahydroquinoxaline derivative which contains, as a substituent, a phenyl group having a sulfonic acid ester structure introduced therein. A compound represented by general formula (1) or a salt thereof is useful as a glucocorticoid receptor agonist, particularly as a therapeutic agent for diseases against which a glucocorticoid receptor agonist (e.g., a steroid) is believed to be effective, such as inflammatory bone/joint diseases, inflammatory ophthalmic diseases (inflammatory ophthalmic diseases in the anterior or posterior segment of an eye).

Abstract: An object of the present invention is to find a novel pharmacological action of a urea compound having a structure represented by the general formula [I]. The urea compound having a structure represented by the general formula [I] or a salt thereof has an excellent therapeutic effect on a TRPV1-mediated disease. In the formula, A represents a lower alkylene group or a lower alkenylene group; R1 represents a hydrogen atom, an alkyl group which may have a substituent or an alkenyl group which may have a substituent; and R2 and R3 are the same or different and represent a hydrogen atom or a lower alkyl group which may be substituted by a monocyclic cycloalkyl group, a polycyclic cycloalkyl group, or an aryl group.